India Pharma Outlook Team | Wednesday, 27 May 2026
Sun Pharma reported a strong financial performance for the fourth quarter of FY26, with Sun Pharma Q4 revenue rising 13.6 per cent to Rs. 14,560 crore and Sun Pharma net profit jumping 26.2 per cent to Rs. 2,714 crore, reflecting healthy growth across key markets and businesses.
The company’s EBITDA stood at Rs. 3,954.2 crore, up 6.4 per cent, while research and development (R&D) investment reached Rs. 975.7 crore, accounting for 6.7 per cent of sales. The strong Sun Pharma Q4 earnings underline the company’s continued growth momentum.
For the full financial year FY26, Sun Pharma FY26 results showed consolidated revenue of Rs. 58,220 crore, registering an 11.9 per cent increase over the previous year. EBITDA grew 16.1 per cent to Rs. 17,731.4 crore, while net profit rose 5 per cent to Rs. 11,479.4 crore. The company invested Rs. 3,554 crore in R&D during the year, representing 6.1 per cent of total sales, highlighting sustained Sun Pharma revenue growth.
The Board of Directors has proposed a final dividend of Rs. 5 per share for FY26. Together with the interim dividend of Rs. 11 per share already paid, the total Sun Pharma dividend FY26 stands at Rs. 16 per share, unchanged from FY25.
Also Read: India's Heatwave Crisis: Prevent Heatstroke Before It Turns Fatal
Speaking on the company’s performance, Kirti Ganorkar, managing director of Sun Pharmaceutical Industries, said FY26 marked several important achievements for the company. He pointed out that Sun Pharma recorded a 0.3 percentage point increase in India market share, its biggest gain since acquiring Ranbaxy.
The Sun Pharma India business continued to be a key growth engine during the quarter. Sales in the domestic market rose 14.8 per cent to Rs. 4,836 crore and contributed 33.2 per cent of the company’s consolidated sales. For the full year, India formulation sales reached Rs. 19,290 crore, growing 14 per cent.
Sun Pharma also strengthened its leadership as an India pharma company. According to the Pharmarack MAT March 2026 report, the company retained its position as India’s top pharmaceutical player, with pharmaceutical market share India increasing from 8.1 per cent to 8.4 per cent. The SMSRC report for November 2025 to February 2026 ranked Sun Pharma number one in prescriptions across 11 doctor categories. The company introduced 11 new products in the fourth quarter and 37 during the full financial year.
Ganorkar said Sun Pharma’s US innovative medicines business crossed the US$1 billion revenue milestone during FY26, while its innovative medicines business outside the US continued to grow steadily. He added that the recently announced Sun Pharma Organon acquisition is expected to support the company’s plans to strengthen its global pharmaceutical presence.
In the US market, formulation sales stood at US$459 million during the quarter, slightly lower by 1.1 per cent because of weakness in the generics business. However, growth in innovative medicines helped balance the decline. The US contributed around 28.8 per cent of Sun Pharma’s total consolidated revenue. For FY26, US formulation sales stood at US$1.9 billion.
Emerging markets delivered strong performance, with formulation sales growing 17.4 per cent to US$306 million in the fourth quarter. Sales in Rest of World markets also increased 10 per cent to US$220 million, underlining the company’s steady international growth and diversified business base.
.jpg)
.jpg)
